{
    "nct_id": "NCT06100913",
    "official_title": "An Open-label Interventional Study to Understand and Quantify the Duration of Humoral Immunological Memory to a Single Dose of Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)",
    "inclusion_criteria": "* Signed informed consent for study.\n* For women of childbearing potential: willing to engage in effective methods of contraception starting at least 28 days prior to vaccination and during the study.\n* Willing to minimize blood and body fluid exposure to others (encourage abstinence, and hand hygiene; discourage contact with blood, vomit, feces without personal protective equipment (PPE) for at least 14 days following vaccine administration.\n* Willing to forgo blood donation until 56 days following vaccination.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* At risk of travel-related or occupational exposure to Ebola virus such as through laboratory, clinical contact, field work, or in the judgment of the investigator.\n* Received any Ebola vaccines or have history of Ebola Virus Disease (EVD).\n* Current or previous diagnosis of immunocompromising condition such as human immunodeficiency virus or other immunosuppressive condition by receiving systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to screening (for corticosteroids: ≥ 10mg/day of prednisone or equivalent) or anticipates the need for immunosuppressive treatment at any time during participation in the study.\n* Pregnant and/or breastfeeding (must have urine pregnancy test on the day of vaccination and during screening visit)\n* Known allergy to any component of the rVSV∆G-ZEBOV-GP vaccine products (VSV, albumin, tris).\n* History of severe local or systemic reactions to any vaccination.\n* Received investigational drug within 5 half-lives or 28 days, whichever is longer, prior to study vaccination.\n* Received or intends to receive vaccines within 28 days prior to or following study vaccination.\n* Received immunoglobulins and/or any blood products within 120 days prior to study vaccination.\n* Clinical evidence of systemic infection or other acute intercurrent illness (e.g. oral temp >38°C or > 100.4°F) less than 72 hours prior to study vaccination.\n* Currently has symptomatic, acute, or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator.\n* History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions, or occupational conditions that in the opinion of the investigator would preclude compliance with the study.\n* Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk in the opinion of the investigator.",
    "miscellaneous_criteria": ""
}